NEW YORK – September 20, 2017 – SIGA Technologies, Inc. (SIGA) (OTCMKTS: SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced that Dr. Phillip L. Gomez, SIGA’sChief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference in New York City at 8:00 am ET on Wednesday, September 27, 2017. Dr. Gomez will provide a corporate update and discuss the company’sinvestigationallead product TPOXX®, an antiviral drug targeting the treatment of orthopoxvirus infections, including smallpox.
To access the live webcast and a copy of the presentation starting that morning, please visit the Investor Relations section of the Company’s website, under Events & Presentations, or click here. A replay will be available for a limited time following the presentation.
ABOUT SIGA TECHNOLOGIES, INC.
SIGA Technologies, Inc. is a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company’slead product is tecovirimat, TPOXX®, also known as ST-246®, an orally administered and IV formulation antiviral drug that targets orthopoxvirus infections, including smallpox. While TPOXX® is not yet approved as safe and effective by the U.S. Food & Drug Administration, it is a novel small-molecule drug that is being delivered to the Strategic National Stockpile under Project BioShield. For more information about SIGA, please visit www.siga.com.
FORWARD-LOOKING STATEMENTS
This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements relating to the submission and approval of TPOXX® by the U.S. Food & Drug Administration. Such forward-looking statements are subject to various known and unknown risks and uncertainties and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. SIGA’s actual results could differ materially from those anticipated by such forward-looking statements due to a number of factors, some of which are beyond SIGA’s control. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in SIGA’s filings with the Securities and Exchange Commission, including SIGA’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and in other documents that SIGA has filed with the SEC. SIGA urges investors and security holders to read those documents free of charge at the SEC’s web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements are current only as of the date on which such statements were made, and except for our ongoing obligations under the United States of America federal securities laws, we undertake no obligation to update publicly any forward-looking statements whether as a result of new information, future events, or otherwise.
Contacts
Investor Relations
David Carey
212-867-1762
dcarey@lazarpartners.com
Media
Glenn Silver
646-871-8485
gsilver@lazarpartners.com
